RNAZ (TransCode Therapeutics) OCF Yield %: -453.04 (As of Jun. 26, 2026)


RNAZ TransCode Therapeutics Inc RNAZ
34 GF Score
Price $4.97
! 1 Warning Sign
View Full Analysis

What is TransCode Therapeutics OCF Yield %?

TransCode Therapeutics RNAZ +10.69% 34 OCF Yield % is -453.04 as of Jun. 26, 2026. GuruFocus rates RNAZ with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,419 Biotechnology companies, TransCode Therapeutics ranks worse than 97.96% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, TransCode Therapeutics's Trailing 12-Month Cash Flow from Operations is $-21.40 Mil, and Market Cap is $4.72 Mil. Therefore, TransCode Therapeutics's OCF Yield % for today is -453.04%.

The historical rank and industry rank for TransCode Therapeutics's OCF Yield % or its related term are showing as below:

RNAZ' s OCF Yield % Range Over the Past 10 Years
Min: -501.45   Med: 0   Max: -436.23
Current: -453.04

During the past 7 years, the highest OCF Yield % of TransCode Therapeutics was -436.23%. The lowest was -501.45%. And the median was %.

RNAZ's OCF Yield % is ranked worse than
97.96% of 1419 companies
in the Biotechnology industry
Industry Median: -8.48 vs RNAZ: -453.04

TransCode Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was %.

TransCode Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

TransCode Therapeutics OCF Yield % Related Terms

TransCode Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for TransCode Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransCode Therapeutics OCF Yield % Chart

TransCode Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial 0.00 0.00 -296.75 -381.98 -311.60

TransCode Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -107.17 -257.89 -182.16 -520.00 -252.20

RNAZ vs ARTL, GLMD, DCOY: OCF Yield % Comparison

For the Biotechnology subindustry, TransCode Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TransCode Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TransCode Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where TransCode Therapeutics's OCF Yield % falls into.


RNAZ
34GF Score
TransCode Therapeutics Inc RNAZ
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransCode Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

TransCode Therapeutics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-19.516 / 6.26311
=-311.60%

TransCode Therapeutics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-4.978 * 4 / 7.89537
=-252.20%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -453.04 mean?
TransCode Therapeutics (RNAZ) has a OCF Yield % of -453.04 as of Jun. 26, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on TransCode Therapeutics and its competitors. According to the industry distribution chart, TransCode Therapeutics ranks #1390 out of 1419 companies in the Biotechnology industry, placing it in the top 98%.
Is TransCode Therapeutics' OCF Yield % too high?
TransCode Therapeutics' current OCF Yield % is -453.04. Based on the distribution chart, TransCode Therapeutics ranks #1390 out of 1419 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TransCode Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does TransCode Therapeutics' OCF Yield % compare to ARTL and GLMD?
According to the Biotechnology industry distribution chart, TransCode Therapeutics ranks #1390 out of 1419 companies for OCF Yield %. This places TransCode Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on TransCode Therapeutics and its competitors. TransCode Therapeutics's current OCF Yield % is -453.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransCode Therapeutics stock overvalued right now?
TransCode Therapeutics (RNAZ) has a current OCF Yield % of -453.04. The current OCF Yield % is -453.04. TransCode Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For TransCode Therapeutics (RNAZ), the current OCF Yield % is -453.04 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TransCode Therapeutics Business Description

Address 6 Liberty Square, No. 2382, Boston, MA, USA, 02109
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
34GF Score

Get the complete analysis for RNAZ

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.97
Price